Loading stock data…
NUVL
$123.25+34.76 (+39.28%)
After Hours$123.45+0.20 (+0.16%)· Last close Jun 9
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nuvalent, Inc. in the Healthcare sector is trading at $123.25 with a market capitalization of $7.1B. Wall Street consensus targets $143.62 (19 analysts), implying a +16.5% move over the next 12 months. The stock is currently near its 52-week high of $123.62, remaining 25.8% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +16.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$123.25
Potential Downside
0%
Whystock Fair Value$123.25
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus19 analysts
Mean target$143.62+16.5%
Range$116.00 – $172.00
Fundamentals
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.15
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-38.32%
Volume
Today's trading volume
51.68M
Recent News
Nuvalent Catapults To Record High On GSK's $10.6 Billion All-Cash Bid
Nuvalent shares catapulted to a record high Tuesday after GSK made an all-cash bid to buy the small biotech company for $10.6 billion.
GSK Bets Big on Cancer With Nuvalent Deal
The $10.6 billion takeover gives GSK a larger role in lung cancer treatments.
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 1.6% and
Stocks to Watch Tuesday: Marvell, Intel, GSK, Vail Resorts
↘️ Marvell Technology (MRVL): Shares of the chip maker dropped 10% after surging nearly 10% on Monday. S&P Dow Jones Indices said earlier it would include the company in the S&P 500 index later this month.
GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover
LONDON, June 9 (Reuters) - GSK has agreed to buy U.-listed cancer drug developer Nuvalent for $10.